Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cassava Sciences Inc

2.19
+0.07003.30%
Post-market: 2.200.0097+0.44%19:48 EDT
Volume:1.06M
Turnover:2.35M
Market Cap:105.79M
PE:-1.43
High:2.27
Open:2.14
Low:2.13
Close:2.12
Loading ...

Cassava Sciences Stock Falls as Alzheimer Drug Misses Targets, To Be Discontinued

Dow Jones
·
25 Mar

Cassava Sciences Shares Drop 21% After Co to Discontinue Development of Alzheimer's Disease Drug

THOMSON REUTERS
·
25 Mar

BUZZ-Cassava falls after stopping development of Alzheimer's drug

Reuters
·
25 Mar

Cassava Sciences' Phase 3 Study of Simufilam Showed No Benefit for Alzheimer's Patients

MT Newswires Live
·
25 Mar

Cassava Sciences Shares Fall 14.3% Premarket After Co to Discontinue Development of Alzheimer's Disease Drug

THOMSON REUTERS
·
25 Mar

Cassava Sciences' controversial Alzheimer's drug fails in second late-stage study

Reuters
·
25 Mar

Cassava to discontinue development of Alzheimer's disease drug

Reuters
·
25 Mar

Cassava Sciences Reports Topline Phase 3 Refocus-Alz Data

THOMSON REUTERS
·
25 Mar

Cassava Sciences Inc - Refocus-Alz Study Did Not Meet Primary, Secondary, or Exploratory Endpoints

THOMSON REUTERS
·
25 Mar

Cassava Sciences Inc - to Discontinue Alzheimer's Program With Simufilam by End of Q2 2025

THOMSON REUTERS
·
25 Mar

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

GlobeNewswire
·
25 Mar

Chinese Drug Administration Accepts Application of Centergate Technologies' Unit for Oxycodone Hydrochloride Tablets

MT Newswires Live
·
14 Mar

Cassava Sciences Amends Bonus Plan After Court Settlement

TIPRANKS
·
12 Mar

Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?

Zacks
·
08 Mar

H.C. Wainwright Sticks to Their Hold Rating for Cassava Sciences (SAVA)

TIPRANKS
·
05 Mar

H.C. Wainwright focused on what results from Cassava’s ReFocus-ALZ might reveal

TIPRANKS
·
05 Mar

Protega Pharmaceuticals collaborates with Wellgistics to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND™

GlobeNewswire
·
04 Mar

Cassava Sciences Reports 2024 Financial Results and Strategic Updates

TIPRANKS
·
04 Mar

Cassava Sciences Q4 2024 GAAP EPS $(0.57) Beats $(0.66) Estimate, $128.6M In Cash And Cash Equivalents

Benzinga
·
03 Mar

BRIEF-Cassava Sciences Q4 Basic EPS USD -0.57

Reuters
·
03 Mar